When Does Keytruda's Exclusivity Expire?
Keytruda (pembrolizumab) is an immunotherapy medication developed by Merck, approved for various types of cancers, including melanoma, non-small cell lung cancer, and others.
Why Is Keytruda's Exclusivity Important?
Keytruda's exclusivity is governed by patents, which prevent generic versions of the medication from being produced and marketed by other companies until the patents expire. When Keytruda's exclusivity expires, generic versions of the medication can enter the market, reducing costs and increasing access to patients.
Keytruda's Patent Expiration Timeline
According to DrugPatentWatch.com[1], Keytruda's original patent (US7902293) expired in 2022 for certain applications, while other patents, including those covering its combination therapy, will expire in the mid-to-late 2020s. However, it's worth noting that new patents, such as those related to Keytruda's formulations or manufacturing processes, may still be pending.
Impact on Pricing and Patient Access
When generic versions of Keytruda become available, pricing is expected to decrease. This can lead to increased access to the medication for patients with cancer and reduced costs for healthcare systems. However, the timeline for generic entry depends on various factors, including the complexity of Keytruda's formulation and the regulatory approvals required.
Competition and New Entrants
Biosimilars, which mimic the active pharmaceutical ingredients of biologic medications like Keytruda, may also be approved by regulatory agencies, such as the US FDA, to provide additional competition. However, the regulatory pathway for biosimilars is more stringent than that for generic small molecule medications, which may impact their availability.
Sources:
[1] DrugPatentWatch.com - Keytruda (pembrolizumab) patents and exclusivity expiration dates.